حمل تطبيق فيزيتا الآن ادخل بروموكود PH15 واحصل على أوسع تغطية، تتبع فوري لطلباتك، وتجربة سلسة ومريحة - كل ذلك في تطبيق واحد.
حمل التطبيق الآن
Lipidnorm 10 mg - 10 Tablet
Box
هذه الصفحة قد لا تغطي جميع المعلومات المذكورة في نشرة الشركة المصنعة المرفقة
الوصف الطبي
Antilipidemic agent used in the treatment of hypercholesterolemia and in the secondary prevention of atherosclerotic cardiovascular diseases.
الدلالة و الاستخدام
-Homozygous familial hypercholesterolemia: Oral: 10 mg once daily.
-Secondary prevention of atherosclerotic cardiovascular events after acute coronary syndrome: Oral: 10 mg once daily.
المكونات النشطة
Ezetimibe
دكاترة مرشحين
لم يتم العثور على دكاترة مرشحين
الجرعة و طريقة الاستعمال
-Administered without regard to meals.
-Should be administered ≥2 hours before or ≥4 hours after bile acid sequestrants.
الاّثار الجانبية
-Increased serum transaminases and hepatotoxicity, myalgia, myopathy and rhabdomyolysis.
-Arthralgia, sinusitis, upper respiratory tract infection and increase in gamma-glutamyl transferase.
نصائح احترازية
-Should not be given to patients suffering from hypersensitivity to ezetimibe.
-Should not be given to patients with active hepatic disease or unexplained persistent elevations in serum transaminases.
-Use with caution in patients with severe renal impairment.
-In case of over dose be ready to tell or show what was taken, how much and when it happened, and seek immediate medical attention. For additional information call us on 16676. Always tell your physician your detailed medical history.
التخزين
Store at room temperature.
تفاعلات الأدوية
-Bile Acid Sequestrants: May decrease the absorption of Ezetimibe.
-Cyclosporine (Systemic): Ezetimibe may increase the serum concentration of Cyclosporine.
-Fenofibrate and Derivatives: May enhance the adverse/toxic effect of Ezetimibe.
الحمل والرضاعة
-Use is contraindicated in pregnant women who require combination therapy with an HMG-CoA reductase inhibitor. If treatment for familial hypercholesterolemia is needed during pregnancy, other agents are preferred.
-It is not known if ezetimibe is present in breast milk, the decision to continue or discontinue breastfeeding during therapy should consider the risk of exposure to the infant and the benefits of treatment to the mother. Use is contraindicated in breastfeeding women who require combination therapy with an HMG-CoA reductase inhibitor.
-Ask your physician before using any medication during pregnancy or lactation.